Patients with severe hypertension (4180/110 mm Hg) require large blood pressure (BP) reductions to reach recommended treatment goals (o140/90 mm Hg) and usually require combination therapy to do so. This 8-week, multicenter, randomized, double-blind, parallelgroup study compared the tolerability and antihypertensive efficacy of the novel direct renin inhibitor aliskiren with the angiotensin converting enzyme inhibitor lisinopril in patients with severe hypertension (mean sitting diastolic blood pressure (msDBP)X105 mm Hg and o120 mm Hg). In all, 183 patients were randomized (2:1) to aliskiren 150 mg (n ¼ 125) or lisinopril 20 mg (n ¼ 58) with dose titration (to aliskiren 300 mg or lisinopril 40 mg) and subsequent addition of hydrochlorothiazide (HCTZ) if additional BP control was required. Aliskiren-based treatment (ALI) was similar to lisinoprilbased treatment (LIS) with respect to the proportion of patients reporting an adverse event (AE; ALI 32.8%; LIS 29.3%) or discontinuing treatment due to AEs (ALI 3.2%; LIS 3.4%). The most frequently reported AEs in both groups were headache, nasopharyngitis and dizziness. At end point, ALI showed similar mean reductions from baseline to LIS in msDBP (ALI À18.5 mm Hg vs LIS À20.1 mm Hg; mean treatment difference 1.7 mm Hg (95% confidence interval (CI) À1.0, 4.4)) and mean sitting systolic blood pressure (ALI À20.0 mm Hg vs LIS À22.3 mm Hg; mean treatment difference 2.8 mm Hg (95% CI À1.7, 7.4)). Responder rates (msDBPo90 mm Hg and/or reduction from baselineX10 mm Hg) were 81.5% with ALI and 87.9% with LIS. Approximately half of patients required the addition of HCTZ to achieve BP control (ALI 53.6%; LIS 44.8%). In conclusion, ALI alone, or in combination with HCTZ, exhibits similar tolerability and antihypertensive efficacy to LIS alone, or in combination with HCTZ, in patients with severe hypertension.
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Introduction
Patients with severe hypertension are at particularly high cardiovascular risk due to the direct and independent relationship between blood pressure (BP) and the risk of mortality due to stroke and ischaemic heart disease. 1 Current treatment guidelines define severe hypertension as BP4160/100 mm Hg (stage 2 hypertension) or 4180/110 mm Hg (grade 3 hypertension), 2, 3 with a treatment target of o140/ 90 mm Hg. Due to the large BP reductions required for patients with severe hypertension to reach their treatment goals, combination therapy is almost invariably required.
Existing antihypertensive therapies are associated with high rates of discontinuation, despite the proven clinical benefit of reducing BP. 4, 5 A recent population-based study of 4100 000 patients with hypertension found that compliance with older drug classes, such as diuretics, b-blockers and calcium channel blockers, was as low as 36-59% after 1 year. 5 Compliance was better with newer treatments, such as angiotensin converting enzyme (ACE) inhibitors (62%) and angiotensin receptor blockers (ARBs; 71%). 5 These differences are suspected to be due to the poor tolerability of some of these drugs. 5 Significant adverse events (AEs) associated with conventional antihypertensive drug classes include fatigue or dizziness in 16% of patients receiving b-blockers, 6 Oedema in up to 70% of patients receiving calcium channel blockers 6, 7 and a dry, non-productive cough in 5-35% of patients receiving treatment with ACE inhibitors. 6, 8, 9 However, this does not explain the poor compliance observed with diuretics, which have few symptomatic side effects. 5 Inhibitors of the renin system, such as ACE inhibitors and ARBs, do not provide optimal suppression of the renin system as they stimulate a reactive increase in plasma renin activity, which may ultimately lead to elevated angiotensin II levels. 10 Consequently, direct inhibition of renin (that is, targeting the renin system at its point of activation) has long been proposed as the most promising means of inhibiting the renin system.
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Aliskiren will be the first in a new class of oral direct renin inhibitors for the treatment of hypertension. Aliskiren is a highly potent inhibitor of human renin in vitro (IC 50 ¼ 0.6 nmol/l) and in healthy volunteers. 12, 13 Studies in patients with mildto-moderate hypertension (ESH-ESC grade 1 or 2, or JNC7 stage 1) have shown that aliskiren provides similar antihypertensive efficacy and tolerability to ARBs, 14, 15 and that addition of hydrochlorothiazide (HCTZ) to aliskiren produces significant additional BP-lowering effects with maintained good tolerability. 16 Aliskiren alone or in combination with HCTZ has also been shown to provide highly effective BP lowering with excellent tolerability over X1-year period of treatment. 17 The aim of the present study was to assess the tolerability and antihypertensive efficacy of aliskirenbased treatment compared with treatment based on the ACE inhibitor, lisinopril, in patients with severe hypertension.
Materials and methods

Study population
This study enrolled 194 patients aged X18 years with uncomplicated severe hypertension (mean sitting diastolic blood pressure (msDBP)X105 mm Hg and o120 mm Hg) from 12 study centres in Germany, 9 in Spain and 5 in Hungary.
Exclusion criteria included a history or evidence of secondary hypertension; antihypertensive treatment with more than three classes of antihypertensive medication; diabetes mellitus requiring insulin treatment; type II diabetes mellitus with poor glucose control (HbA 1C 48% at Visit 1); diagnosed heart failure; history of myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention; angina pectoris; potentially lifethreatening arrhythmia or symptomatic arrhythmia or other life-threatening disease; any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of the study drugs; and known or suspected contraindications to the study medications.
The study was performed in compliance with the Guidelines for Good Clinical Practice and the Declaration of Helsinki of the World Medical Association, and received approval by the appropriate independent ethics committees. All participants gave written informed consent before any study-related procedure.
Study design
This was an 8-week, randomized, double-blind, active-controlled, parallel-group study of aliskiren compared with lisinopril (both with the optional addition of HCTZ to achieve BP control) in adult patients with uncomplicated severe hypertension. Owing to the severity of the disease, the use of a placebo treatment was not employed. Lisinopril was selected as an active control because it is commonly used to treat patients with severe hypertension.
The primary objective of this study was to compare the tolerability of aliskiren-based treatment with treatment based on the ACE inhibitor, lisinopril. The BP-lowering efficacy of these two treatments was a secondary objective of this study.
The study consisted of three periods ( Figure 1 ). Eligibility for study entry was assessed at an initial study visit and eligible patients then entered a washout phase (period 1) of up to 10 days, during which all other antihypertensive medications were withdrawn. However, due to the severity of hypertension, and the potential increased cardiovascular risk associated with the withdrawal of antihypertensive medication, the washout period was designed to minimize the length of time patients remained untreated. Consequently, antihypertensive medications were withdrawn for a minimum of 3 days and all participants with an msDBPX105 mm Hg and o120 mm Hg at the end of the washout period proceeded immediately to the active treatment phase of the study (period 3). Patients with msDBPX85 mm Hg and o105 mm Hg after the washout phase entered a single-blind placebo runin of 1-3 weeks (period 2). During this period, BP was monitored weekly up to a maximum of 3 weeks to assess eligibility for randomization (msDBPX 105 mm Hg and o120 mm Hg). Participants who failed to meet the eligibility criteria after 3 weeks were discontinued from the study. Any patient with an msDBPX120 mm Hg and/or a mean sitting systolic blood pressure (msSBP)X200 mm Hg at any time during the washout or single-blind placebo run-in periods was immediately discontinued from the study.
In period 3, all patients who met the inclusion criteria were randomized in a 2:1 ratio to receive aliskiren 150 mg or lisinopril 20 mg once daily. BP was assessed weekly for the first 2 weeks and every 2 weeks thereafter. For patients with msDBPX 110 mm Hg or msSBPX180 mm Hg at the end of week 1, or with msDBPX95 mm Hg or msSBPX160 mm Hg at the end of week 2, the treatment dose was doubled (to aliskiren 300 mg or lisinopril 40 mg). Subsequent addition of HCTZ 25 mg was permitted for these patients if msDBP was X95 mm Hg or msSBP remained X160 mm Hg at weeks 2 or 4, or if msDBP was X90 mm Hg or msSBP was X140 mm Hg at week 6 ( Figure 1 ). For patients who did not require early titration at weeks 1 or 2, doses were increased to aliskiren 300 mg, or lisinopril 40 mg at the end of week 4 if BP was not controlled to target levels (msDBPo90 mm Hg and msSBPo140 mm Hg).
Aliskiren 150 mg and matching placebo were provided as film-coated tablets. Lisinopril 20 mg, lisinopril 40 mg and matching placebo were provided as identically appearing capsules, as were HCTZ 25 mg and matching placebo. Patients were requested to take the study medication orally with water at approximately 0800 hours, except on the day of a study visit.
Randomization was performed by the interactive voice response system provider using a validated system that automates the random assignment of treatment groups to randomization numbers. All patients, investigator staff, persons performing the assessments and data analysts remained blinded to the identity of the treatment from the time of randomization until database lock.
Each investigator site was supplied with a computer loaded with electronic data capture software and investigator site staff were trained to use this system by Novartis personnel. All required data were entered into the electronic case report forms (eCRFs) by designated investigator site personnel before transfer to Novartis via a secure Virtual Private Network. Novartis staff reviewed the eCRFs entered by investigational staff for completeness and accuracy and instructed the site personnel to make any required corrections or additions. Quality control audits of all key safety and efficacy data in the database were carried out before database lock.
Tolerability assessments
The safety population was defined as all randomized patients who received at least one dose of study medication. All AEs, serious adverse events (SAEs) and use of concomitant medications were recorded at each study visit. Non-directive questioning was used to elicit information on AEs; for all AEs, the severity, relationship to study drug and duration were assessed, and any action taken was recorded.
Evaluations of routine blood chemistry, haematology and urine values, as well as a physical examination, vital signs and ECG recordings, were performed at screening, randomization (start of period 3) and after the completion of the study.
Efficacy assessments BP and pulse rate were measured at follow-up visits on weeks 1, 2, 4, 6 and 8 of the double-blind treatment period. Sitting and standing BP was measured at trough (2473 h post-dose) from the arm in which the highest sitting DBP was found at the first study visit, using a calibrated standard sphygmomanometer. Three measurements were taken at each visit and the average of the three measurements was used for analysis. Pulse rate was measured for 30 s immediately before the first sitting BP measurement.
Statistical analyses
Patients were randomized in a 2:1 ratio between aliskiren and lisinopril treatment groups, respec- tively. The lisinopril treatment group contained fewer patients as lisinopril served solely as a reference drug for the evaluation of the tolerability of aliskiren. A sample size of 153 completed patients (102 patients in the aliskiren-based treatment group and 51 patients in the lisinopril-based treatment group) was considered sufficient to evaluate the overall tolerability profile of the aliskiren-and lisinopril-based regimens and to satisfy the regulatory requirement for the assessment of safety. Assuming a dropout rate of 15%, a total of X180 patients were to be randomized. No precise power computations were carried out as this was a safety study and was not powered for any specific end point. There were no pre-set margins for the assessment of safety in terms of AE rates or other safety parameters.
The primary assessment of tolerability was based on the frequency of AEs, laboratory abnormalities and SAEs. The frequency distribution of patients who experienced orthostatic BP changes (a decrease of at least 20 mm Hg in SBP or a decrease of at least 10 mm Hg in DBP when moving from a sitting to a standing position) was also assessed.
All efficacy variables were analysed for the intentto-treat population, which was defined as all randomized patients who had a baseline (start of period 3) measurement and at least one post-baseline efficacy measurement. The key efficacy variables were change from baseline in msDBP and msSBP. The proportion of responders (patients with msDBPo90 mm Hg and/or X10 mm Hg reduction from baseline in msDBP) was also assessed.
Descriptive statistics were provided for each efficacy variable. For each patient, the last postbaseline measurement of a variable during the double-blind period was carried forward as the end point measurement for the variable to be analysed. The study was not powered for efficacy comparisons.
Results
Patient characteristics
A total of 194 patients were enrolled in the study, of whom 183 were randomized to receive active treatment (aliskiren, n ¼ 125; lisinopril, n ¼ 58). Of these, 138 patients were randomized directly into the active treatment phase. Fifty-six patients entered the optional single-blind run-in period, of whom 45 were subsequently randomized to receive study treatment; the other 11 patients were excluded for abnormal test procedure results (n ¼ 7; this includes patients who did not meet BP inclusion criteria), withdrawal of consent (n ¼ 3) and administrative problems (n ¼ 1).
The treatment groups were generally similar with respect to demographics and baseline characteristics ( Table 1 ). All but one of the patients in the study was Caucasian (99.5%) and a little more than half of the patients were male (56.8%). The mean age of patients was 55 years with a mean duration of hypertension of 9 years. Nearly half of patients were obese with 46.4% of patients having a body mass index of at least 30 kg/m 2 . The msDBP and msSBP values at baseline were 108.3 and 162.8 mm Hg, respectively, and these values were similar between the two treatment groups.
Most randomized patients (83.1%) had one or more past or continuing medical conditions, the most common of which was hypercholesterolaemia. There were no notable differences between the two treatment groups in the incidence of past or continuing medical conditions (Table 1 ) or in the use of concomitant medications (55.2% in each group).
Mean exposure to drug treatment was similar for both treatment groups (aliskiren, 52.2 days; lisinopril, 53.9 days) and close to the planned duration of treatment of 56 days. Overall, 165 patients completed the study and the completion rate was similar in the two treatment groups (aliskiren, 88.8%; lisinopril, 93.1%). The main reasons for discontinuation were AEs (n ¼ 6; 3.3%), withdrawal of consent (n ¼ 5; 2.7%) and unsatisfactory therapeutic effect (n ¼ 3; 1.6%). At the end of the study, 33 patients (26.4%) were receiving aliskiren 150 mg, 25 patients (20.0%) were being treated with aliskiren 300 mg and 67 patients (53.6%) were receiving aliskiren 300 mg plus HCTZ 25 mg. In the lisinopril group, 20 patients (34.5%) were being treated with lisinopril 20 mg, 12 patients (20.7%) were receiving lisinopril 40 mg and 26 patients (44.8%) were receiving lisinopril plus HCTZ 25 mg.
Tolerability
Adverse events. Aliskiren-and lisinopril-based treatments were well tolerated. The incidence of AEs was similar in the two treatment groups; 32.8% of patients in the aliskiren group and 29.3% of patients in the lisinopril group reported at least one AE during the double-blind treatment period. There were no notable differences between treatment groups in the type of AEs observed (Table 2 ) and the majority of AEs were mild or moderate in severity. The most frequently reported AEs were headache (8.7%), nasopharyngitis (2.7%), dizziness (1.6%) and fatigue (1.6%). Only 3.3% of patients withdrew from the study due to AEs with no more than one person reporting the same AE as a reason for discontinuation.
The proportion of patients reporting AEs that were suspected by the investigator to be related to the study drugs was similar in the aliskiren group (5.6%) and the lisinopril group (5.2%). The only individual AE suspected to be related to study treatment in more than one patient was headache (two patients in the aliskiren group and one in the lisinopril group).
No deaths occurred during the study. Three SAEs were reported by two patients, both in the lisinopril group; one patient suffered severe angina pectoris and myocardial infarction (leading to hospitalization and percutaneous coronary intervention with stent implantation) and one patient suffered appendicitis. These events were not suspected to be related to study treatment.
Laboratory values and physical signs
Notable changes in vital signs occurring at singletime points included an increase in mean SBP for one patient in the aliskiren group, and decreased pulse rate for one patient in the lisinopril group; neither of these changes was reported as an AE. The incidence of patients with orthostatic BP changes at each visit was low (less than 7% at any visit in any treatment group) and similar to baseline, and there were no notable differences between treatment groups.
There were no notable changes in haematological parameters in patients receiving aliskiren-based treatment (n ¼ 125) during the course of the study. In the lisinopril treatment group (n ¼ 58), three patients recorded abnormal haematological values: one patient demonstrated an elevated (475%) platelet count, one patient demonstrated an elevated white blood cell count (450%) and, as is often observed with ACE inhibitor therapy, [18] [19] [20] one patient recorded a 420% decrease in haemoglobin level. The haematological profiles of all other patients in the lisinopril treatment group remained normal throughout the course of the study.
For most biochemistry parameters, changes from baseline were small and there were no meaningful Metabolic syndrome was defined as any three of the following: waist circumference 4102 cm for men or 488 cm for women; triglycerides X1.69 mmol/l (X150 mg/dl); high-density lipoprotein cholesterol o1.04 mmol/l (o40 mg/dl) for men or o1.29 mmol/l (50 mg/dl) for women; SBPX130 or DBPX85 mm Hg; fasting glucoseX6.1 mmol/l (X110 mg/dl). Other than lisinopril given as part of this study.
Tolerability of aliskiren in patients with severe hypertension RH Strasser et al differences between treatment groups. Overall, mean uric acid levels increased from baseline in both treatment groups (by 39.2 and 45.7 mmol/l for the aliskiren and lisinopril groups, respectively).
There was a slight increase in creatinine levels in the aliskiren group (1.5 mmol/l) compared with a slight decrease in the lisinopril group (À0.6 mmol/l). Few individual patients showed notable abnormal laboratory values. Low serum potassium levels (o3.5 mmol/l) occurred in three patients (5.2%) in the lisinopril group and three patients (2.5%) in the aliskiren group. There was only one case each of serum potassium elevation (45.5 mmol/l) and blood urea nitrogen elevation (414.28 mmol/l), both in the aliskiren group. None of the abnormal laboratory values was reported as an AE.
Antihypertensive efficacy
Of the 125 patients randomized to receive the aliskiren-based treatment regimen, the majority was titrated from 150 to 300 mg (n ¼ 92; 73.6%), and a little more than half (n ¼ 67; 53.6%) received add-on treatment with HCTZ 25 mg. Similar rates of titration (n ¼ 38; 65.5%) and add-on therapy (n ¼ 26; 44.8%) were observed with lisinopril-based treatment (Figure 2 Marked reductions in msDBP and msSBP were observed after 1 week of treatment in both groups, and absolute BP values in the aliskiren-and lisinopril-based treatment groups were similar at all time points during this study (Figure 3) .
The majority of patients in both treatment groups exhibited a successful response to treatment (msDBPo90 mm Hg, and/or X10 mm Hg reduction from baseline) at the week 8 end point. The proportion of responders for the aliskiren-based regimen (81.5%) was similar to that observed with the lisinopril-based regimen (87.9%).
Discussion
Characteristics that physicians look for when choosing an antihypertensive drug include sustained BP lowering efficacy (both alone and in combination with other agents), a good tolerability profile, and convenient dosing to ensure good compliance. This is the first study to investigate the tolerability and efficacy of the orally effective, direct renin inhibitor aliskiren in patients with severe hypertension (JNC7 stage 2, or ESH-ESC grade 3). The study showed that aliskiren-based therapy (with the optional addition of HCTZ to achieve BP control) was well tolerated by patients with severe hypertension, and provided similar BP-lowering effects to therapy based on the ACE inhibitor lisinopril. The incidence of AEs with aliskiren-based treatment was low, and similar to that observed with lisinopril-based therapy. Moreover, the most frequently reported AEs in both groups were headache, nasopharyngitis and dizziness, events that are commonly observed in studies of antihypertensive drugs in patients with severe hypertension. [21] [22] [23] Aliskiren-based treatment did not result in any significant changes in laboratory or biochemistry values. Despite ACE inhibitors being commonly associated with a dry non-productive cough (5-35% of patients), the incidence of cough following lisinopril-based treatment was unusually low in this study (2%).
The good tolerability of aliskiren-based therapy observed in the present study in patients with severe hypertension is consistent with previous studies that have shown the placebo-like safety and tolerability of aliskiren monotherapy or combinations of aliskiren and HCTZ in patients with mild-tomoderate hypertension (JNC7 stage 1, or ESH-ESC grade 1 or 2). 14, 16 Aliskiren, alone or in combination with HCTZ, also demonstrated excellent long-term tolerability in a 12-month clinical trial in patients with mild-to-moderate hypertension. 17 The design of the present study allowed for the addition of HCTZ 25 mg in patients who did not achieve BP control with aliskiren or lisinopril monotherapy. Although the present study was not designed to have sufficient statistical power for comparisons of antihypertensive efficacy, aliskirenbased therapy provided BP-lowering effects similar to those of lisinopril-based treatment in patients with severe hypertension.
In conclusion, the results of the present study show that aliskiren-based treatment (with the addition of HCTZ as needed for BP control) is well tolerated and provides highly effective BP lowering similar to that of a lisinopril-based treatment regimen in patients with severe hypertension. An antihypertensive regimen based on the direct renin inhibitor aliskiren therefore represents a well-tolerated and effective option for the treatment of severe hypertension. What is known about the topic K Patients with severe hypertension (4180/110 mm Hg) require large reductions in BP to achieve recommended BP levels and as a result combination antihypertensive therapy is almost invariably required. K The renin system is a key regulator of volume and BP homeostasis and inhibitors of the renin system (for example, ACE inhibitors, angiotensin receptor blockers (ARBs)) are widely used in the treatment of hypertension. K The direct renin inhibitor (DRI), aliskiren, will be the first in a new class of antihypertensive therapy. Studies in patients with mild-to-moderate hypertension have shown that aliskiren provides similar antihypertensive efficacy and tolerability to ARBs.
What this study adds K This is the first study to evaluate the tolerability and efficacy of a direct renin inhibitor in patients with severe hypertension. K Aliskiren, with the optional addition of the diuretic, hydrochlorothiazide, is well tolerated in patients with severe hypertension. K Aliskiren-based treatment provides effective BP reductions in patients with severe hypertension, similar to an equivalent regimen based on the ACE inhibitor, lisinopril.
